Vaccines Europe - 18 Nov 2018
Since its launch a decade ago, the European Innovative Medicines Initiative (IMI), a leading public–private partnership in life sciences, has catalysed scientific breakthroughs and the development of strategies to address complex challenges in various biomedical fields. This review in Nature examines the impact of the initiative on vaccine development.
Read the publication here
Members area
